HK Stock Market Move | China Sanjiang (02198) surged over 7% after profit announcement. It is expected that the shareholder's net profit for the first half of the year will increase by approximately 100% to 130% year-on-year.
China Sanjiang Chemical (02198) opened more than 7% higher after its profit announcement, and by the time of the report, it had risen by 7.01% to HK$2.9, with a trading volume of HK$284,200.
CHINA SANJIANG (02198) opened more than 7% higher after the profit announcement, reaching a 7.01% increase by the time of publication, at HK$2.9, with a turnover of HK$284,200.
On the news front, on July 13th, CHINA SANJIANG announced that the group is expected to achieve a net profit attributable to equity holders of RMB 600 million to RMB 700 million for the six months ending on June 30, 2026. In comparison, the group achieved a net profit attributable to equity holders of about RMB 301 million for the six months ending on June 30, 2025, representing an increase of approximately 100% to 130% compared to the same period in 2025.
The announcement stated that the expected increase in the net profit attributable to equity holders is mainly due to the group's continuous dynamic adjustment of its procurement strategy, sources, raw material composition, and production mix in response to the current commodity market conditions.
Related Articles

Financial Report Preview | ASML Holding NV ADR (ASML.US) Q2 Financial Report to be Released Soon AI Belief Faces a Crucial Test

Sichuan Kelun Pharmaceutical (002422.SZ): The Phase III clinical study on the first-line treatment of locally advanced or metastatic PD-L1 negative non-squamous non-small cell lung cancer with sacituzumab govitecan (sac-TMT) in combination with pembrolizumab has achieved its primary endpoint.

HK Stock Market Move | Chifeng Jilong Gold Mining (06693) fell more than 4% in the morning, with second-quarter net profit expected to decline by 19% to 27% quarter-on-quarter.
Financial Report Preview | ASML Holding NV ADR (ASML.US) Q2 Financial Report to be Released Soon AI Belief Faces a Crucial Test

Sichuan Kelun Pharmaceutical (002422.SZ): The Phase III clinical study on the first-line treatment of locally advanced or metastatic PD-L1 negative non-squamous non-small cell lung cancer with sacituzumab govitecan (sac-TMT) in combination with pembrolizumab has achieved its primary endpoint.

HK Stock Market Move | Chifeng Jilong Gold Mining (06693) fell more than 4% in the morning, with second-quarter net profit expected to decline by 19% to 27% quarter-on-quarter.

RECOMMEND





